Search hospitals

>

Indiana

>

South Bend

Memorial Hospital of South Bend

Claim this profile

South Bend, Indiana 46601

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Ovarian Cancer

Conducts research for Breast cancer

Conducts research for Prostate Cancer

388 reported clinical trials

5 medical researchers

Photo of Memorial Hospital of South Bend in South BendPhoto of Memorial Hospital of South Bend in South BendPhoto of Memorial Hospital of South Bend in South Bend

Summary

Memorial Hospital of South Bend is a medical facility located in South Bend, Indiana. This center is recognized for care of Breast Cancer, Lung Cancer, Ovarian Cancer, Breast cancer, Prostate Cancer and other specialties. Memorial Hospital of South Bend is involved with conducting 388 clinical trials across 441 conditions. There are 5 research doctors associated with this hospital, such as Thomas Reid, MD, Nibal Saad, Muhammad O. Toor, and Nonyem A. Onujiogu.

Area of expertise

1

Breast Cancer

Global Leader

Memorial Hospital of South Bend has run 87 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
Stage IV
2

Lung Cancer

Global Leader

Memorial Hospital of South Bend has run 62 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at Memorial Hospital of South Bend

Ovarian Cancer

Breast Cancer

Breast cancer

Testicular cancer

Pancreatic Cancer

Pancreatic Carcinoma

Cancer

Lung Cancer

Endometrial Cancer

Uterine Cancer

Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Memorial Hospital of South Bend?

Where is Memorial Hospital of South Bend located?

Who should I call to ask about financial aid or insurance network?

What insurance does Memorial Hospital of South Bend accept?

What awards or recognition has Memorial Hospital of South Bend received?